Full text is available at the source.
Targeting glioblastoma through nano- and micro-particle-mediated immune modulation
Using tiny particles to change the immune response against glioblastoma
AI simplified
Abstract
Glioblastoma Multiforme (GBM) has a 5-year survival rate of only 5.4%.
- GBM is characterized by significant challenges in delivering chemotherapy across the blood brain barrier.
- The immune environment surrounding GBM is influenced by tumor signaling, leading to immunosuppression.
- There is conflicting evidence regarding whether pro-inflammatory or anti-inflammatory therapies are more effective in treating GBM.
- Particle delivery systems may enhance the transport of immune-stimulatory molecules to target GBM.
- Literature from the past 3 years has investigated the combination of particle delivery systems and immunotherapy for GBM treatment.
AI simplified